search
Back to results

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer (AIVAA)

Primary Purpose

Lung Cancer

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Ascorbic acid
Normal Saline
Sponsored by
The Canadian College of Naturopathic Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy Exclusion Criteria: ECOG status greater than 2 Previously received IVC within 6 months prior to randomization Biochemical deficiency in G6PD Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min Currently taking insulin or warfarin History of severe renal dysfunction or hemochromatosis Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency Currently taking an investigational product or participation in an investigational study within the past 30 days Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Intravenous Vitamin C

    Normal Saline

    Arm Description

    1g/kg IVC administered twice weekly for 6 months.

    Equivalent volume normal saline administered twice weekly for 6 months.

    Outcomes

    Primary Outcome Measures

    Change in Quality of Life
    Participant reported quality of life (QOL) measured using the Functional Assessment of Cancer Therapy - Lung (FACT-L). FACT-L is a validated tool for assessing QOL in patients with lung cancer. FACT scores are normalized to values between 0-100, where 0 is the worst QOL and 100 is the best QOL imaginable. Each chemotherapy cycle is 3 weeks in length.

    Secondary Outcome Measures

    Chemotherapy-Related Toxicities
    Frequency of adverse events (AE) which are commonly experienced by patients undergoing chemotherapy. Measured using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 31 symptoms were selected by the investigators.
    Frequency of Discontinuation of Chemotherapy
    Patients often discontinue chemotherapy due to side effects. The investigators will monitor the incidence of stopping chemotherapy and compare the number of patients who stop chemotherapy in both arms.
    Change in General Symptom Burden
    Measured using the Edmonton Symptom Assessment Scale, which measures 9 symptoms commonly experienced by cancer patients. Each symptom is rated on a scale of 0-10, where 0 is the best symptom and 10 is the worst symptom. Each chemotherapy cycle is 3 weeks in length.
    Change in C-Reactive Protein Levels
    The investigators will monitor the changes in C-reactive protein (CRP), a common indicator of systemic inflammation. Mean changes in CRP will be compared between arms. Each chemotherapy cycle is 3 weeks in length.
    Tumour Progression
    The investigators will monitor tumour progression using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, which measures the incidence of complete response, partial response, stable disease, and progressive disease during treatments.
    Survival
    The incidence of all cause mortality will be compared between arms.
    Safety
    The investigators will monitor the incidence of all adverse events in both arms to add to the safety profile of IVC in this population.
    Cytotoxicity
    The investigators will assess the ability of IVC to bring serum ascorbate levels to at least 15mM, which is the hypothesized level at which cytotoxic effects may occur. Levels 15mM or above will be considered adequate.

    Full Information

    First Posted
    April 24, 2023
    Last Updated
    May 8, 2023
    Sponsor
    The Canadian College of Naturopathic Medicine
    Collaborators
    Ottawa Hospital Research Institiute
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05849129
    Brief Title
    Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
    Acronym
    AIVAA
    Official Title
    Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer: A Double Blind, Placebo Controlled, Phase II Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 1, 2023 (Anticipated)
    Primary Completion Date
    July 1, 2029 (Anticipated)
    Study Completion Date
    July 1, 2030 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    The Canadian College of Naturopathic Medicine
    Collaborators
    Ottawa Hospital Research Institiute

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lung Cancer

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    90 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intravenous Vitamin C
    Arm Type
    Experimental
    Arm Description
    1g/kg IVC administered twice weekly for 6 months.
    Arm Title
    Normal Saline
    Arm Type
    Placebo Comparator
    Arm Description
    Equivalent volume normal saline administered twice weekly for 6 months.
    Intervention Type
    Drug
    Intervention Name(s)
    Ascorbic acid
    Other Intervention Name(s)
    Vitamin C
    Intervention Description
    High dose ascorbic acid delivered intravenously
    Intervention Type
    Other
    Intervention Name(s)
    Normal Saline
    Other Intervention Name(s)
    Sodium Chloride Solution
    Intervention Description
    0.9% NaCl solution
    Primary Outcome Measure Information:
    Title
    Change in Quality of Life
    Description
    Participant reported quality of life (QOL) measured using the Functional Assessment of Cancer Therapy - Lung (FACT-L). FACT-L is a validated tool for assessing QOL in patients with lung cancer. FACT scores are normalized to values between 0-100, where 0 is the worst QOL and 100 is the best QOL imaginable. Each chemotherapy cycle is 3 weeks in length.
    Time Frame
    Baseline, Chemo cycles 1-4, 6 months, 12 months
    Secondary Outcome Measure Information:
    Title
    Chemotherapy-Related Toxicities
    Description
    Frequency of adverse events (AE) which are commonly experienced by patients undergoing chemotherapy. Measured using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 31 symptoms were selected by the investigators.
    Time Frame
    12 months
    Title
    Frequency of Discontinuation of Chemotherapy
    Description
    Patients often discontinue chemotherapy due to side effects. The investigators will monitor the incidence of stopping chemotherapy and compare the number of patients who stop chemotherapy in both arms.
    Time Frame
    6 months
    Title
    Change in General Symptom Burden
    Description
    Measured using the Edmonton Symptom Assessment Scale, which measures 9 symptoms commonly experienced by cancer patients. Each symptom is rated on a scale of 0-10, where 0 is the best symptom and 10 is the worst symptom. Each chemotherapy cycle is 3 weeks in length.
    Time Frame
    Baseline, chemo cycles 1-4, 6 months, 12 months
    Title
    Change in C-Reactive Protein Levels
    Description
    The investigators will monitor the changes in C-reactive protein (CRP), a common indicator of systemic inflammation. Mean changes in CRP will be compared between arms. Each chemotherapy cycle is 3 weeks in length.
    Time Frame
    Baseline, chemo cycles 1-4, 6 months, 12 months
    Title
    Tumour Progression
    Description
    The investigators will monitor tumour progression using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, which measures the incidence of complete response, partial response, stable disease, and progressive disease during treatments.
    Time Frame
    12 months
    Title
    Survival
    Description
    The incidence of all cause mortality will be compared between arms.
    Time Frame
    24 months
    Title
    Safety
    Description
    The investigators will monitor the incidence of all adverse events in both arms to add to the safety profile of IVC in this population.
    Time Frame
    6 months
    Title
    Cytotoxicity
    Description
    The investigators will assess the ability of IVC to bring serum ascorbate levels to at least 15mM, which is the hypothesized level at which cytotoxic effects may occur. Levels 15mM or above will be considered adequate.
    Time Frame
    12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy Exclusion Criteria: ECOG status greater than 2 Previously received IVC within 6 months prior to randomization Biochemical deficiency in G6PD Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min Currently taking insulin or warfarin History of severe renal dysfunction or hemochromatosis Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency Currently taking an investigational product or participation in an investigational study within the past 30 days Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Dugald Seely, ND, MSc
    Phone
    613-792-1222
    Ext
    2
    Email
    dseely@thechi.ca
    First Name & Middle Initial & Last Name or Official Title & Degree
    Mark Legacy, BSc, CCRP
    Phone
    613-792-1222
    Ext
    1
    Email
    mlegacy@thechi.ca

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    Individual participant data will not be shared with other researchers. Cumulative data not present in the manuscript or on this website may be shared upon request.

    Learn more about this trial

    Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

    We'll reach out to this number within 24 hrs